Systems‐based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
Abstract Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously developed quantitative systems pharmacology model...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
格式: | 圖書 |
出版: |
Wiley,
2023-07-01T00:00:00Z.
|
主題: | |
在線閱讀: | Connect to this object online. |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
成為第一個發表評論!